Salud financiera de hoja de balance de VolitionRx

Salud financiera controles de criterios 0/6

VolitionRx tiene un patrimonio de los accionistas total de $-16.6M y una deuda total de $4.5M, lo que sitúa su ratio deuda-patrimonio en -27.2%. Sus activos y pasivos totales son $19.4M y $36.1M respectivamente.

Información clave

-27.2%

Ratio deuda-patrimonio

US$4.52m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$11.77m
Patrimonio	-US$16.62m
Total pasivo	US$36.05m
Activos totales	US$19.43m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

What Type Of Shareholders Own The Most Number of VolitionRx Limited (NYSEMKT:VNRX) Shares?

Nov 30

Análisis de la situación financiera

Pasivos a corto plazo: VNRX tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: VNRX tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: VNRX tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: VNRX tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: VNRX tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: VNRX tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 9.6% cada año

Salud financiera de hoja de balance de VolitionRx

Salud financiera controles de criterios 0/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Price target decreased by 7.9% to US$3.47

Consensus revenue estimates decrease by 16%, EPS upgraded

New minor risk - Profitability

Consensus revenue estimates increase by 23%, EPS downgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

VolitionRx Limited, Annual General Meeting, Jul 02, 2024

VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech

Consensus revenue estimates fall by 43%

New minor risk - Profitability

Forecast to breakeven in 2026

Full year 2023 earnings: EPS and revenues miss analyst expectations

VolitionRx Limited announced that it has received $0.1 million in funding

Volitionrx Limited Appoints Andrew Retter as Chief Medical Officer, Effective April 1, 2024

High number of new directors

VolitionRx Limited announced that it has received €2.5 million in funding

Consensus revenue estimates decrease by 22%, EPS upgraded

New major risk - Negative shareholders equity

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 7.2% to US$3.66

VolitionRx Limited Presents Breakthrough Liquid Biopsy Blood Test Method for Early-Stage Cancer

New minor risk - Profitability

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Market cap size

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $16.51 million.

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $16.51 million.

Consensus revenue estimates decrease by 45%

Forecast to breakeven in 2025

Price target decreased by 11% to US$4.94

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $7.525 million.

Price target decreased by 9.7% to US$5.21

Chief Scientific Officer recently bought US$72k worth of stock

Volitionrx Limited Announces Resignation of Dr. Jason Terrell as Chief Medical Officer

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Volition Announces the Launch of the Nu.Q(R) Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories

Consensus revenue estimates fall by 19%

VolitionRx Limited Appoints Mickie Henshall as Independent Director

Price target decreased to US$6.71

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 94%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

VolitionRx Limited Launches its Nu.Q® Vet Cancer Test in Asia

VolitionRx Limited Appoints Sharon Ballesteros as U.S. Head of Quality and Development Process

Consensus revenue estimates increase by 253%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.092 loss in 3Q 2020)

Consensus revenue estimates fall to US$530.0k

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.12 loss in 2Q 2020)

VolitionRx Limited Demonstrates Promising Results in Covid-19 Risk Stratification and Disease Monitoring

VolitionRx Limited(NYSEAM:VNRX) dropped from Russell 3000E Value Index

Consensus forecasts updated

Lead Independent Director recently bought US$503k worth of stock

Consensus forecasts updated

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 1Q 2020)

Non-Executive Director has left the company

Consensus revenue estimates fall to US$903.7k

Full year 2020 earnings released: US$0.45 loss per share (vs US$0.41 loss in FY 2019)

Do Institutions Own VolitionRx Limited (NYSEMKT:VNRX) Shares?

VolitionRx Limited has completed a Follow-on Equity Offering in the amount of $20.000001 million.

Insider recently sold US$54k worth of stock

This Insider Has Just Sold Shares In VolitionRx Limited (NYSEMKT:VNRX)

New 90-day high: US$6.50

Volitionrx Limited Announces Executive Appointments

Price target raised to US$7.66

Market Sentiment Around Loss-Making VolitionRx Limited (NYSEMKT:VNRX)

New 90-day high: US$4.46

Have Insiders Been Selling VolitionRx Limited (NYSEMKT:VNRX) Shares This Year?

New 90-day high: US$3.79

VolitionRx Limited Appoints Dr. Tom Butera DVM to its Board of Directors, Audit, Compensation and Nominations and Governance Committees

Volition Launches Nu.Q Vet Cancer Screening Test in the U.S

What Type Of Shareholders Own The Most Number of VolitionRx Limited (NYSEMKT:VNRX) Shares?

VolitionRx Limited to Present COVID-19 Data at MEDICA 2020